Exavir Therapeutics is a preclinical-stage biotechnology company focused on eliminating HIV and other viral infections using a broad modality-agnostic approach. The company is beginning its work with long-acting antiviral therapeutics. Led by co-founder and President Alborz Yazdi, Exavir intends to use its recent funding to expand development efforts. The company closed a $4M Seed financing led by AlleyCorp with participation from Gilead Sciences. Exavir is based in New York and Omaha, NE. The company’s work targets a large global market: more than 37 million people live with HIV worldwide and over $30B is spent annually on antiretroviral therapies.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

May 2022